New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompare5-Amino-1MQ vs Cardiogen

5-Amino-1MQ vs Cardiogen

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
5-Amino-1MQ
Anti-Aging & Longevity
Cardiogen
Summary
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Half-Life
Estimated 4–8 hours
Short (minutes); gene-regulatory effects persist longer
Admin Route
Oral
SubQ, Oral
Research
Typical Dose
50–100 mg
10 mg per day
Frequency
Once to twice daily
Daily for 10–30 days
Key Benefits
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
Side Effects
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
Stacks With